TONMYA Beats Placebo on FIQR in Both Phase 3 Fibromyalgia Trials
BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) reported that TONMYA fibromyalgia treatment beat placebo on both the symptoms and function domains of the Fibromyalgia Impact Questionnaire-Revised (FIQR) at Week 14 in two Phase 3 trials. The result was significant at p≤0.001 in RESILIENT and nominally significant at p0.01 in RELIEF.
Tonix presented the analysis at the IASP 2026 World Congress on Pain in Bangkok, held October 26-30, 2026. That is about 11 months after the November 2025 commercial launch of the drug, which the FDA approved on August 15, 2025.